drugset

drugset / Trial / NCT06003751

A Study of PER-001 in Participants With Diabetic Retinopathy

NCT06003751 ↗

Phase 2 Completed 27 enrolled Perfuse Therapeutics, Inc.

RandomizedSequentialSingle-blindTreatment

Summary

This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.

Timeline

Start: 2023-08-05
Primary completion: 2025-04-03
Completion: 2025-12-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PER-001	Unknown	—	Intravitreal

Indications